SCHEMBL21484909

SCHEMBL21484909

N#CC(=Cc1cccc(C(=O)O)c1)C(=O)Nc1nc(-c2ccccc2)cs1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.51
PARP1 P09874 2/20 0.50
PHGDH O43175 1/20 0.48
SCD O00767 1/20 0.48
NR1H4 Q96RI1 1/20 0.47
GSTO1 P78417 1/20 0.47
MAPT P10636 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 1/20 0.47
CSNK2A1 P68400 1/20 0.47
KDM4A O75164 1/20 0.46
KDM4B O94953 1/20 0.46
KDM5C P41229 1/20 0.46
KDM5B Q9UGL1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484907 1.00 LMNA (0.51) LMNAPARP1PHGDHSCDNR1H4
SCHEMBL28511750 0.89 KDM4E (0.52) LMNAPARP1GSTO1MAPTMEN1
SCHEMBL28511749 0.89 KDM4E (0.52) LMNAPARP1GSTO1MAPTMEN1
SCHEMBL21484826 0.89 CSNK2A1 (0.55) LMNAPARP1SCDGSTO1MAPT
SCHEMBL21484829 0.89 CSNK2A1 (0.55) LMNAPARP1SCDGSTO1MAPT
SCHEMBL21484899 0.85 MAPT (0.53) LMNAPARP1MAPTMEN1KMT2A
SCHEMBL21484778 0.85 ERBB2 (0.51) LMNAPARP1GSTO1MAPTMEN1
SCHEMBL21484901 0.85 MAPT (0.53) LMNAPARP1MAPTMEN1KMT2A
SCHEMBL21484629 0.85 EGFR (0.62) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL21506046 0.84 SIRT5 (0.52) LMNAMAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
CN-112313229-A Substituted aminothiazoles as inhibitors of nucleases 马萨里克大学 2021-02-02 CN disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 LMNA 522/4885PARP1 62/4885PHGDH 4048/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 LMNA 522/4885PARP1 62/4885PHGDH 4048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.